Metsera, a NYC-based clinical-stage biopharmaceutical company, raised $290M in funding.
The round was led by ARCH Venture Partners with participation from other healthcare investors including F-Prime Capital, GV, Mubadala Capital, Newpath Partners, SoftBank Vision Fund 2 and other undisclosed investors.
The company intends to use the funds to expand operations and its R&D sector.
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape.
The portfolio of injectable and oral development programs is sourced from the company’s proprietary library of over 20,000 gut hormone peptides and peptide/antibody conjugates. Development programs include parallel strategies and are focused on multiple next-generation targets and combinations. These include:
- GLP-1 portfolio: led by an injectable, fully-biased GLP-1 receptor agonist in Phase 1 clinical trials with a potential class-leading duration of effect
- A dual amylin/calcitonin receptor agonist (DACRA) engineered for class-leading duration of effect which is being combined with the GLP-1 receptor agonist
- A unimolecular GGG (GLP-1, GIP, Glucagon) engineered for class-leading duration of effect and combination with DACRA
- An oral peptide delivery platform, including two IND-ready candidates with potential best-in-class bioavailability and multiple first-in-class oral follow-on candidates
- A range of other early-stage programs and delivery modalities
FinSMEs
18/04/2024